XTSX
TELO
Market cap3mUSD
Oct 08, Last price
0.05CAD
1D
-9.09%
1Q
11.11%
Jan 2017
-98.90%
IPO
-97.37%
Name
Telo Genomics Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.00%
Rev. gr., 5y
%
Revenues
0
Net income
-3m
L+0.21%
CFO
-2m
L-5.30%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges. The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer. Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019. Its headquarters are located in Toronto, Canada.
Key people
Hugh Rogers
Interim Chairman of the Board · since 2018
Interim Chairman of the Board · since 2018
Ryan Cheung
Chief Financial Officer, Director · since 2018
Kevin Little
Chief Scientific Officer · since 2017
Sabine Mai
Director · since 2018
Ferenc Somogyvari
Director · since 2016
Independent Director · since 2011
Independent Director · since 2011
Legal address
Hornby Street
Suite 605-815
Vancouver, BC V6Z 2E6
CA
Suite 605-815
Vancouver, BC V6Z 2E6
CA
Headquarters
MaRS Centre,South Tower
101 College Street
Suite 200
Toronto, ON M5G 1L7
CA
101 College Street
Suite 200
Toronto, ON M5G 1L7
CA
Previous name
Plicit Capital Corp.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||